IRVINE, Calif., Oct. 26 /PRNewswire-FirstCall/ -- IDM Pharma, Inc. (Nasdaq: IDMI), a biotechnology company focused on the development of innovative cancer therapies, today announced details on clinical data presentations evaluating three of the Company's pipeline compounds to be presented at upcoming medical congresses.
Specific presentation details are as follows:
Connective Tissue Oncology Society (CTOS) -- Seattle, Wash.
Oral presentation -- Thursday, November 1, 1:30 p.m. PDT
"Osteosarcoma: Improved Outcome of Muramyl Tripeptide (MTP) to Cisplatin, Doxorubicin, High Dose Methotrexate +/- Ifosfamide."
Dr. Paul Meyers, principal investigator, vice chairman, department of pediatrics at Memorial Sloan Kettering Cancer Center
The 39th Congress of International Society of Pediatric Oncology (SIOP) -- Mumbai, India
Poster presentation -- Friday, November 2, 4:30 -- 6 a.m. EDT
"Lung and Bone Specific Site-Directed Therapy of Osteosarcoma"
Dr. Johannes Wolff, professor of pediatrics, The University of Texas M.D. Anderson Cancer Center in Houston
Dr. Maurizio Ghisoli, fellow, pediatric oncology and hematology, The University of Texas M.D. Anderson Cancer Center in Houston
International Society for Biological Therapy of Cancer (iSBTc) -- Boston, Mass.
Oral presentation (Vaccines/Dendritic Cells) -- Sunday, November 4, 8:45 - - 11 a.m. EST
"Phase 2 Trial of a 10-epitope CTL Vaccine, IDM-2101, in Metastatic NSCLC Patients: Induction of Immune Responses and Clinical Efficacy"
Dr. Minal Barve, practice director, Mary Crowley Medical Research Center
|SOURCE IDM Pharma, Inc.|
Copyright©2007 PR Newswire.
All rights reserved